AppClone's Next-Generation CAR-T Therapy Receives Designation as Orphan Drug

South Korean biotech firm AppClone has achieved a significant milestone with its next-generation CAR-T therapy, 'Nespeseal (AT101)', receiving designation as a development-stage orphan drug by the Ministry of Food and Drug Safety. This designation provides AppClone with various benefits, including extended marketing authorization, simplified data submission, and exclusive data protection, which can increase development efficiency and secure market exclusivity. The therapy's core technological differentiation lies in AppClone's unique antibody and CAR-T technology, utilizing a humanized antibody 'H1218' that improves drug persistence and induces a stronger anti-cancer effect. The therapy has shown impressive results in clinical trials, with an objective response rate of 94% and complete remission rate of 68%.

Key Takeaways:

AppClone's next-generation CAR-T therapy, 'Nespeseal (AT101)', has been designated as a development-stage orphan drug by the Ministry of Food and Drug Safety, granting benefits such as extended marketing authorization and exclusive data protection.
The therapy's core technological differentiation lies in AppClone's unique antibody and CAR-T technology, utilizing a humanized antibody 'H1218' that improves drug persistence and induces a stronger anti-cancer effect.
The therapy has shown impressive results in clinical trials, with an objective response rate of 94% and complete remission rate of 68%.
The Ministry of Food and Drug Safety's designation of orphan drugs in the development stage provides benefits such as extended product approval period (from 5 years to 10 years), simplified data submission, and exclusive data protection.
The global cell therapy market is expected to grow at a CAGR of approximately 40% to reach $29 billion by 2029, with CD19 targeted therapy accounting for 74% of the market share.
AppClone's therapy, 'Nescell (AT101)', is a personalized treatment for patients with relapsed or refractory blood cancer, utilizing a humanized antibody 'H1218' that improves drug persistence and induces a stronger anti-cancer effect.

Statistics:

The global cell therapy market reached $3.74 billion in 2023.
The market is expected to grow at a CAGR of approximately 40% to reach $29 billion by 2029.
CD19 targeted therapy accounts for 74% of the market share, reaching $2.76 billion in 2023 and expected to expand to $22 billion by 2029.
AppClone's therapy, 'Nespeseal (AT101)', has shown an objective response rate of 94% and complete remission rate of 68% in clinical trials.

Sources:

Abclon (Original Press Release)
Ministry of Food and Drug Safety (MFDS)
Korea Biotechnology Industry Organization